Royal Philips just amped up its digital offerings to make clinical trials faster, more efficient and easier to conduct remotely, a function more important than ever as the COVID-19 pandemic continues.
Dubbed the Clinical Trial Accelerator, appropriately enough, the new capabilities will join the Philips HealthSuite system, which already offers cloud-based services and tools to a wide variety of healthcare organizations, the company said in a release.
The latest set of capabilities will allow researchers to collect, secure and analyze large amounts of data from multiple sources, including patient-reported data and remote-monitoring feeds.
“[W]ith Clinical Trial Accelerator, we have created a tailored set of capabilities to support life science organizations,” said Dale Wiggins, general manager for the HealthSuite platform at Philips.
As a HIPAA-compliant, cloud-based system that can accommodate a variety of data sources, the trial accelerator will enable patient-centric trials at home at a time when more and more drugmakers need to run clinical trials in ways that protect participants and researchers from exposure to the novel coronavirus.
Empowering patients and making it easier to stay connected and contribute to a trial can be key to their personal adherence to trial protocols and to the overall success of a study, Philips said. Data security and regulatory compliance are also important, of course.
The new HealthSuite capabilities are designed to tackle all these challenges, the company said, “helping life science organizations reach their goals faster and supporting greater flexibility in trial design.”